Novartis | NVS - PE Price to Earnings


Novartis reported 21.36 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.96 0.93 Jun/2026
Amgen 18.07 1.77 Jun/2026
AstraZeneca 25.34 4.25 Jun/2026
Bausch Health Companies 12.85 0 Jun/2026
Biogen 23.23 9.53 Jun/2026
Bristol-Myers Squibb 16.14 7.06 Jun/2026
Corcept Therapeutics 188.23 74.66 Jun/2026
Drreddys Laboratories 19.25 0.98 Mar/2026
Eli Lilly 32.9 7.37 Jun/2026
Gilead Sciences 13.51 4.2 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
Glaxosmithkline 15.09 3.43 Mar/2026
J&J 29.43 4.9 Jun/2026
Merck 32.26 15.74 Jun/2026
Novartis 22.41 2.24 Jun/2026
Novartis 21.36 3.57 Mar/2026
Pacira 35.68 2.9 Jun/2026
Perrigo 27.45 31.51 Mar/2026
Pfizer 11.48 2.16 Jun/2026
Phibro Animal Health 13.82 4.04 Dec/2025
Prestige Brands 11.89 3.75 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 18.96 7.12 Jun/2026
Sanofi 20.87 5.12 Mar/2026
Supernus Pharmaceuticals 65.37 21.16 Jun/2026
Zoetis 10.58 8.22 Jun/2026